Web Exclusives
Web Exclusives | December 14, 2021
Promising antitumor activity and a tolerable safety profile were found in patients with previously treated gastric or gastroesophageal cancer treated with trifluridine/tipiracil combined with ramucirumab.
Web Exclusives | December 14, 2021
Insertion-deletion rate and high tumor mutation burden in advanced gastric cancer was found to be associated with favorable progression-free survival and overall survival in patients treated with nivolumab.
Web Exclusives | December 14, 2021
Treatment with surufatinib in combination with toripalimab is associated with promising responses and manageable adverse events in previously treated gastric or gastroesophageal junction adenocarcinoma.
Web Exclusives | December 14, 2021
Post-hoc analysis of the CheckMate-032 study found PD-L1 expression by combined positive score was more closely associated with nivolumab and ipilimumab therapy efficacy compared with percentage of positive tumor cells PD-L1 expression in advanced gastric/gastroesophageal junction cancer.
Web Exclusives | December 14, 2021
Progression-free survival and overall survival improved more after treatment with ramucirumab plus paclitaxel compared with placebo plus paclitaxel in Asian patients with advanced gastric and gastroesophageal junction cancer who were previously treated with chemotherapy.
Web Exclusives | December 14, 2021
Progression-free survival and overall survival improved more after treatment with ramucirumab plus paclitaxel compared with placebo plus paclitaxel in Asian patients with advanced gastric and gastroesophageal junction cancer who were previously treated with chemotherapy.
Web Exclusives | December 14, 2021
Nivolumab with paclitaxel plus ramucirumab as second-line therapy in patients with advanced gastric cancer demonstrated promising responses with manageable treatment-related adverse events.
Web Exclusives | November 19, 2021
A recently released MYLUNG study found that most patients with untreated metastatic NSCLC tested for ≥1 biomarkers, but <50% of patients had ≥5 biomarker tests.
Web Exclusives | November 19, 2021
Recently released clinical trial results evaluating the effect of early integration of interdisciplinary supportive care found improvement in quality of life, mood, and nutritional status in patients with NSCLC.
Web Exclusives | November 19, 2021
Caregivers and patients report better understanding of precision medicine and reduced patient anxiety with implementation of a therapeutic patient education program.
Web Exclusives | November 19, 2021
Study results reveal that KRAS G12C mutations vary according to sex and ethnicity in patients with cancer.
Web Exclusives | November 16, 2021
Nivolumab plus chemotherapy in patients with advanced gastric cancer, esophageal adenocarcinoma, or gastroesophageal junction cancer led to significantly higher health-related quality-of-life scores than in patients receiving chemotherapy alone.
Web Exclusives | November 16, 2021
KEYNOTE-590 study results demonstrate improved overall survival and progression-free survival across subgroups for treatment-naïve patients with advanced esophageal cancer receiving pembrolizumab combined with chemotherapy.
Web Exclusives | November 16, 2021
Patients with previously treated advanced or metastatic gastric cancer receiving sintilimab showed a modest response rate and an acceptable safety profile.
Web Exclusives | November 16, 2021
Recently released clinical trial results show that bavituximab in combination with pembrolizumab had promising antitumor activity and was well-tolerated in patients with advanced gastric or gastroesophageal cancer.
Web Exclusives | November 16, 2021
Patients with treatment-naïve advanced or metastatic esophageal squamous-cell carcinoma receiving combination toripalimab and chemotherapy saw significant progression-free survival and overall survival improvement.
Web Exclusives | November 16, 2021
Clinical trial results demonstrate nivolumab combined with chemotherapy conveys improvement in overall response rate and progression-free survival in patients with recurrent or advanced gastric cancer.
Web Exclusives | October 25, 2021
Researchers reported that molecular testing in patients with non–small-cell lung cancer aged ≥70 years is performed at the same proportions as in younger patients.
Web Exclusives | October 25, 2021
Analysis of EGFR, KRAS, and PIK3CA gene mutation rates in patients with lung cancer revealed a correlation with clinical characteristics that may have a significant effect on personalized cancer treatment.
Web Exclusives | October 25, 2021
A recently released report indicates that low-dose computed tomography targeted screening for lung cancer confers patient health and public health benefits.
Web Exclusives | October 25, 2021
A large cohort analysis of treatment status, treatment regimen, and outcomes in patients with KRAS-mutated advanced NSCLC revealed valuable information for future clinical trials.
Web Exclusives | October 25, 2021
CheckMate 649 study results demonstrate that nivolumab combined with chemotherapy has an acceptable safety profile and improves survival outcomes in patients with advanced gastric/esophageal cancer.
Web Exclusives | October 25, 2021
Japanese study data demonstrate second-line pembrolizumab improved overall survival with an acceptable safety profile compared with chemotherapy in patients with advanced esophageal cancer.
Web Exclusives | October 25, 2021
An expert panel released recommendations for the clinical management of patients with advanced esophageal cancer and gastroesophageal junction adenocarcinoma.
Web Exclusives | October 25, 2021
Nivolumab added to either ipilimumab or chemotherapy improved overall survival in patients with advanced esophageal squamous-cell carcinoma, according to data from the CheckMate-648 study.
Web Exclusives | October 25, 2021
A comprehensive analysis of immune checkpoints in gastric adenocarcinoma found that ICOSLG and CD70 are associated with immune infiltration and may potentially serve as prognostic biomarkers.
Web Exclusives | October 25, 2021
Phase 2 study results of second-line trastuzumab deruxtecan use in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer revealed an antitumor response.
Web Exclusives | October 19, 2021
Recently released analysis of 18F-DCFPyL PET/CT accuracy demonstrated improved diagnostic capability in men with biochemical recurrence of prostate cancer.
Web Exclusives | October 19, 2021
NaF PET imaging study demonstrates an increased sensitivity over Tc99m-MDP bone scans for new lesion detection in patients with stable metastatic prostate cancer.
Web Exclusives | October 19, 2021
Salvage radiotherapy decisions for patients with recurrent prostate cancer after prostatectomy change after 18F-fluciclovine PET/CT reveals higher positive findings than conventional imaging.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512